Andrew Dickinson serves as Gilead’s Chief Financial Officer, responsible for the oversight of the company’s global finance, corporate development, information technology, operations and strategy organizations.
Andy joined Gilead in 2016 and prior to his current role served as head of the company’s corporate development and strategy group. In that role, Andy drove all of Gilead’s licensing, partnership and acquisition transactions and guided investments into new areas. Prior to his tenure at Gilead, Andy was the global Co-Head of Healthcare Investment Banking at Lazard. Earlier in his career, he served as General Counsel and Vice President of Corporate Development at Myogen Inc., which was acquired by Gilead in 2006.
Andy received his bachelor’s degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and his law degree from Loyola University of Chicago.
He currently serves on the board of directors for Galapagos NV in connection with its partnership with Gilead. Andy also serves on the board of directors of Sutter Health, a nonprofit hospital system based in California, and previously served on the board of directors of the Fosun Pharma and Kite joint venture in China, which was established in 2017.
View All Leaders